The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus

Lekh N Dahal, Robert N Barker, Frank J Ward*

*Corresponding author for this work

Research output: Contribution to journalLetter

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder characterized by fluctuating levels of immune response hyperactivity, high serum titers of nucleic antigen-specific autoantibodies, and persistent production of type-I interferon (IFN)1 One route to controlling SLE has been to exploit the properties of T cell lymphocyte costimulation inhibitor (CTLA-4), a selective costimulation inhibitor, which suppresses autoantigen-specific T cell response intensity2.

Original languageEnglish
Article number190678
Pages (from-to)302-304
Number of pages3
JournalJournal of Rheumatology
Volume47
Issue number2
Early online date1 Dec 2019
DOIs
Publication statusPublished - Feb 2020

Fingerprint Dive into the research topics of 'The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus'. Together they form a unique fingerprint.

  • Equipment

    Iain Fraser Cytometry Centre

    Andrea Holme (Manager), Linda Duncan (Senior Application Scientist), Ailsa Laird (Technician) & Kate Burgoyne (Technician)

    Institute of Medical Sciences

    Research Facilities: Facility

  • Cite this